# Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia

> **NCT00768612** · PHASE2 · WITHDRAWN · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SCA-136 50mg/day
- **DRUG:** SCA-136 150 mg/day
- **DRUG:** SCA-136 300mg/day
- **DRUG:** Risperidone 4mg/day

## Key facts

- **NCT ID:** NCT00768612
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-11
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768612, "Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00768612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*